local_hospital

State Health Services Organisation

Address
Limassol Old Road 215, 2029 Nicosia, Cyprus

State Health Services Organisation - Infectious Disease & Addiction Research

State Health Services Organisation is a clinical research center dedicated to advancing treatment strategies for critical public health challenges. The center conducts innovative trials addressing complex medical conditions, with particular emphasis on developing evidence-based interventions that can transform patient outcomes in both acute and chronic disease management.

  • Opioid Use Disorder treatment optimization and relapse prevention strategies
  • COVID-19 therapeutic interventions and immune modulation approaches
  • Biomarker identification for predicting treatment response and relapse vulnerability

The organization specializes in addiction medicine research, investigating novel pharmacological agents like ketamine as complementary therapies for opioid use disorder. Their work includes identifying predictive biomarkers for relapse and extending abstinence periods. Additionally, the center participates in multi-center respiratory infection trials through the STRIVE platform, evaluating immune modulation strategies for hospitalized patients with acute respiratory infections including COVID-19, utilizing adaptive trial designs to rapidly assess therapeutic efficacy and safety.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
2
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 4 other sites in Cyprus

description
Trial volume
2
Outperforms 25% of sites
public
Therapeutic diversity
3areas
Outperforms 75% of sites
groups
Sponsor diversity
2sponsors
Outperforms 25% of sites

Therapeutic Area Benchmark — Cyprus

Select a therapeutic area to compare against other sites in Cyprus.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Cyprus

Market Share

Country: Cyprus

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in State Health Services Organisation

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Evaluation of Abatacept and Placebo in Hospitalized Adults with COVID-19: A Randomized, Controlled Trial on Immune Modulation StrategiesUniversity Of MinnesotaPhase IIINot RecruitingNov 2023Aug 2025

IMP list

lock Showing 1 of 2 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Abatacept1Unknown2023-11-282023-11-28

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.